Good Tumor Response to Chemoradioimmunotherapy in dMMR/MSI-H Advanced Colorectal Cancer: A Case Series

Zhou, Chengjing1,2; Jiang, Ting1; Xiao, Yajie3; Wang, Qiaoxuan1; Zeng, Zhifan1; Cai, Peiqiang4; Zhao, Yongtian3; Zhao, Zhikun3; Wu, Dongfang3; Lin, Hanqing3; Sun, Chao3; Zhang, Rong5; Xiao, Weiwei1; Gao, Yuanhong1

2021-12-15

10.3389/fimmu.2021.784336

Frontiers in Immunology   影响因子和分区

1664-3224

PurposeImmune checkpoint blockade has led to a significant improvement of patient survival in metastatic colorectal cancer (CRC) with DNA mismatch repair-deficiency (dMMR)/microsatellite instability-high (MSI-H). However, not all these patients are sensitive to monoimmunotherapy. We firstly presented a case series of advanced dMMR/MSI-H CRCs treating with PD-1 inhibitor-based chemoradioimmunotherapy (CRIT). Methods and MaterialsWe assessed the short-term efficacy and safety of CRIT in advanced dMMR/MSI-H CRCs, and also did next-generation sequencing (NGS) assays. ResultsOur analysis included five advanced dMMR/MSI-H CRCs who have received toripalimab-based CRIT. Toripalimab was given 240mg every three weeks, and the radiation dose was 45-50 gray in 25 fractions. Chemotherapy regimens consisted of CAPOX in three patients, capecitabine in one patient, and mFOLFOX6 in one patient. Initially, two patients displayed complete response (CR), and three patients achieved partial response (PR) on imaging findings. Afterwards, one PR patient was confirmed pathological complete response after surgery, leading to three CR cases in total. Hematological toxicity was the most common adverse effect, and only two patients developed mild immune-related adverse effects besides. All the treatment-related adverse events were under control. Based on the NGS results, the median intratumor heterogeneity was 0.19 (range 0-0.957), which was less in CR patients than PR patients (P = 0.019). Genetic mutations at DNA damage repair genes and the JAK1 gene were also observed. ConclusionsFor advanced dMMR/MSI-H CRC, anti-PD-1 based CRIT is effective and safe. Further studies are required to better clarify the potential role and mechanism of CRIT as a viable therapeutic strategy in this population.

chemotherapy radiotherapy immunotherapy programmed cell death protein 1 inhibitor colorectal cancer

SCI

英语

其他

Immunology

Immunology

WOS:000738550600001

FRONTIERS MEDIA SA

Web of Science

1.Sun Yat Sen Univ, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Dept Radiat Oncol,Canc Ctr, Guangzhou, Peoples R China
2.Southern Univ Sci & Technol, Sch Med, Shenzhen, Peoples R China
3.YuceBio Technol Co Ltd, Dept Med, Shenzhen, Peoples R China
4.Sun Yat Sen Univ, Dept Med Imaging & Intervent Radiol, State Key Lab Oncol South China, Canc Ctr ,Collaborat Innovat Ctr Canc Med, Guangzhou, Peoples R China
5.Sun Yat Sen Univ, Dept Endoscopy & Laser, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med,Canc Ctr, Guangzhou, Peoples R China

Zhou, Chengjing,Jiang, Ting,Xiao, Yajie,et al. Good Tumor Response to Chemoradioimmunotherapy in dMMR/MSI-H Advanced Colorectal Cancer: A Case Series[J]. Frontiers in Immunology,2021,12.

Zhou, Chengjing.,Jiang, Ting.,Xiao, Yajie.,Wang, Qiaoxuan.,Zeng, Zhifan.,...&Gao, Yuanhong.(2021).Good Tumor Response to Chemoradioimmunotherapy in dMMR/MSI-H Advanced Colorectal Cancer: A Case Series.Frontiers in Immunology,12.

Zhou, Chengjing,et al."Good Tumor Response to Chemoradioimmunotherapy in dMMR/MSI-H Advanced Colorectal Cancer: A Case Series".Frontiers in Immunology 12(2021).